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Background. Kawasaki disease is characterized by systemic vasculitis of unknown etiology. Previous genetic studies have identiﬁed
certain candidate genes associated with susceptibility to KD and coronary artery lesions. Host innate immune response factors are
involved in modulating the disease outcome. The aim of this study was to investigate CLEC5A (C-type lectin domain family
5) genetic polymorphisms with regards to the susceptibility and outcome of KD. Methods. A total of 1045 subjects (381 KD
patients and 664 controls) were enrolled to identify 4 tagging single-nucleotide polymorphisms (tSNPs) of CLEC5A (rs1285968,
rs11770855, rs1285935, rs1285933) by using the TaqMan Allelic Discrimination Assay. The Hardy-Weinberg equilibrium was
assessed in cases and controls, and genetic eﬀects were evaluated by the chi-square test. Results. No signiﬁcant associations
were noted between the genotypes and allele frequency of the 4 CLEC5A tSNPs between controls and patients. In the
patients, polymorphisms of CLEC5A showed no signiﬁcant association with coronary artery lesion formation and intravenous
immunoglobulin treatment response. Conclusions. This study showed for the ﬁrst time that polymorphisms of CLEC5A are not
associated with susceptibility to KD, coronary artery lesion formation, and intravenous immunoglobulin treatment response in a
Taiwanese population.
1.Introduction
Kawasaki disease (KD) is characterized by acute, febrile, and
systemic vasculitis and was ﬁrst described by Kawasaki et
al. in 1974 [1]. In developed countries, KD is the leading
cause of acquired heart diseases in children [2, 3]. KD occurs
worldwide and particularly in Japan, Korea, and Taiwan
and mainly aﬀects children less than 5 years of age [4–
6]. The most serious complication of KD is the occurrence
of coronary artery lesions (CALs) [7, 8]. The prevalence
of KD in children younger than 5 years is the highest in
Japan, followed by Korea and Taiwan, and lowest in Europe.
Previous studies have either failed to identify causative
pathogens for KD or reported discrepant results [9–11].
Therefore, it is possible that a genetic background plays an
important role in the pathogenesis of KD.
CLEC5A (C-type lectin domain family 5, member A;
also known as myeloid DAP12-associating lectin (MDL-1))2 Journal of Biomedicine and Biotechnology
contains a C-type lectin-like fold similar to the natural-
killer T-cell C-type lectin domains and is associated with
a 12-kDa DNAX-activating protein (DAP12) on myeloid
cells [12–14]. Signaling via this complex constitutes a
signiﬁcant activation pathway in myeloid cells and plays an
important role in immune defense. Recently, it has been
demonstrated that CLEC5A acts as a signaling receptor
for proinﬂammatory cytokine release, and that blockade of
CLEC5A-mediated signaling attenuates the production of
proinﬂammatory cytokines by macrophages infected with
dengue virus [14]. In contrast, it has been demonstrated that
MDL-1stimulationinducesasigniﬁcantamountofRANTES
and macrophage-derived chemokine (MDC) production in
cooperation with signaling through TLR in mouse myeloid
cells [15]. Furthermore, there is ample evidence that activa-
tion of peripheral blood monocytes/macrophages [16–18],
proinﬂammatory cytokines [16], and the RANTES gene play
a central role during acute KD [19, 20]. A persistent or
increased expression of chemokine genes in the convalescent
phase in patients is associated with coronary artery lesions
[17, 19]. In addition, inﬁltration by the cells is notable in
aﬀectedtissuesinautopsycasesandinskinbiopsyspecimens
from KD patients [21].
However, no CLEC5A genetic association with KD has
previously been reported. To gain further understanding of
the genetic role of CLEC5A in the pathogenesis of KD, the
aim of our study was to determine if any CLEC5A SNPs are
associatedwithsusceptibilitytoKD,CALformation,orIVIG
treatment response in Taiwanese children.
2. Patientsand Methods
2.1. Patients Studied. All study cases were children enrolled
from Chang Gung Memorial Hospital, Kaohsiung Medical
Center, between 2001 and 2009, who fulﬁlled the diagnostic
criteria for KD. All patients were treated with IVIG (2g/kg)
and aspirin as per our previous studies [7, 8, 18]. This study
was approved by the Institutional Review Board of Chang
Gung Memorial Hospital. Blood samples were collected after
informed consent was obtained from parents or guardians.
CAL formation was deﬁned as the internal diameter of
the coronary artery measuring at least 3mm (4mm if the
subject was over the age of 5 years) or the internal diameter
of a segment at least 1.5 times that of an adjacent segment, as
observed in echocardiography [8, 22]. IVIG responsiveness
wasdeﬁnedasdefervescencewithin48hafterthecompletion
of IVIG treatment and no recurrence of fever (temperature
> 38◦C) for at least 7 days after IVIG with marked
improvement or normalization of inﬂammatory signs [7, 8].
2.2. DNA Extraction. B l o o dc e l l sw e r es u b j e c t e dt oD N A
extraction by treating them ﬁrst with 0.5% SDS lysis buﬀer
and then protease K (1mg/mL) for digestion of nuclear
protein for 4h at 60◦C. Total DNA was harvested by using a
Gentra extraction kit followed by 70% alcohol precipitation
as described in our previous report [23].
Table 1: Basal characteristics of the patients with Kawasaki disease
a n dn o r m a lc o n t r o l s .
Characteristic Patients with KD Normal controls
N = 381 N = 664
Male gender, no. (%) 247 (64.8%) 314 (55.2%)
Mean (SD) age
(years) 1.7 ±1.65 .7 ±4.9
Age range (years) 0–11 0–51
CAL formation, no.
(%) 37 (9.7%)
IVIG resistance, no.
(%) 49 (12.9%)
CAL: coronary artery lesion; IVIG: intravenous immunoglobulin; SD:
standard deviation.
2.3. SNPs Selection for CLEC5A. We selected tagging SNPs
(tSNPs) of CLEC5A from the release 2.0 Phase II data of
the HapMap Project (http://www.hapmap.org). tSNPs were
chosen according to the following criteria: r2 ≥ 0.8, the
minor allele frequency (MAF) ≥ 10% in the Han Chinese
population, and tSNPs located in exon or 1kb UTR.
2.4. Genotyping. Genotyping was carried out using the Taq-
Man Allelic Discrimination Assay (Applied Biosystems, Fos-
ter city, Calif, USA) as per our previous report [24]. The
polymerase chain reaction (PCR) was performed using a 96-
well microplate with an ABI9700 Thermal Cycler. After PCR,
ﬂuorescence was detected and analyzed using System SDS
software version 1.2.3.
2.5. Statistical Analysis. JMP 8.0 for Windows was used for
analysis. Statistical diﬀerences between cases and controls in
genotype and allele frequency were assessed using the χ2 test
or Fisher’s exact test. The Hardy-Weinberg equilibrium was
assessed using the χ2 test with 1 degree of freedom. Statistical
diﬀerences in genotype and allele frequency of KD patients
with or without CAL formation and patients with IVIG re-
sistance/responsiveness were assessed using the χ2 test. The
Bonferronitestwasusedtocorrectformultipletests.Linkage
disequilibrium (LD) was assessed for any pair of SNPs, and
haplotypeblocksweredeﬁnedusingthedefaultsettingofthe
Haploview software 4.1 (Broad Institute, Cambridge, Mass,
USA).
3. Results
3.1. Lack of Association between CLEC5A tSNPs and the
Susceptibility of KD. A total of 381 KD patients and 664 con-
trols were included in this study (Table 1). The distribution
of CLEC5A genotypes was in accordance with the Hardy-
Weinberg equilibrium for both cases and controls (Table 2).
However, none of the tSNPs was signiﬁcantly associated
with the genotype or allele frequency of the controls or KD
patients under 3 genetic models (dominant, recessive, or
allelic models) (Table 2).Journal of Biomedicine and Biotechnology 3
Table 2: Genotype and allele frequencies of the CLEC5A gene in controls and patients with Kawasaki disease.
Genotype Case (%)
(n = 381)
Control
(%)
(n = 664)
Allele Case (%)
(n = 381)
Control (%)
(n = 664)
Genotype P
value
Dominant
P value
Recessive P
value
Allelic P
value
rs1285968
GG 70 (18.5) 141 (21.5) G 325 (42.9) 596 (45.4)
0.484 0.488 0.245 0.261 AG 185 (48.8) 314 (47.9) A 433 (57.1) 716 (54.6)
AA 124 (32.7) 201 (30.6)
rs11770855
GG 88 (23.5) 147 (22.5) G 366 (48.9) 623 (47.8)
0.877 0.643 0.718 0.615 AG 190 (50.8) 329 (50.5) A 382 (51.1) 681 (52.2)
AA 96 (25.7) 176 (27.0)
rs1285935
AA 29 (7.6) 51 (7.8) A 208 (27.4) 341 (26.1)
0.640 0.390 0.923 0.519 GA 150 (39.5) 239 (36.5) G 552 (72.6) 967 (73.9)
GG 201 (52.9) 364 (55.7)
rs1285933
TT 9 (2.4) 30 (4.6) T 136 (18.0) 263 (20.2)
0.194 0.488 0.072 0.228 CT 118 (31.2) 203 (31.1) C 620 (82.0) 1041 (79.8)
CC 251 (66.4) 419 (64.3)
Table 3: Genotype and allele frequencies of the CLEC5A gene in patients with Kawasaki disease with or without coronary artery lesion
formation (CAL).
Genotype CAL (%)
(n = 37)
Without
(%)
(n = 336)
Allele CAL (%)
(n = 37)
Without
(%)
(n = 336)
Genotype P
value
Dominant
P value
Recessive P
value
Allelic P
value
rs1285968
GG 6 (17.1) 62 (18.5) G 31 (44.3) 286 (42.6)
0.784 0.568 0.849 0.781 AG 19 (54.3) 162 (48.2) A 39 (55.7) 386 (57.4)
AA 10 (28.6) 112 (33.3)
rs11770855
GG 8 (22.2) 78 (23.6) G 35 (48.6) 323 (48.9)
0.968 0.921 0.849 0.958 AG 19 (52.8) 167 (50.6) A 37 (51.4) 337 (51.1)
AA 9 (25.0) 85 (25.8)
rs1285935
AA 3 (8.1) 26 (7.8) A 21 (28.4) 184 (27.5)
0.985 0.864 0.941 0.867 GA 15 (40.5) 132 (39.4) G 53 (71.6) 486 (72.5)
GG 19 (51.4) 177 (52.8)
rs1285933
TT 1 (2.7) 7 (2.1) T 12 (16.2) 119 (17.9)
0.840 0.633 0.812 0.724 CT 10 (27.0) 105 (31.5) C 62 (83.8) 547 (82.1)
CC 26 (70.3) 221 (66.4)
3.2. Lack of Association between CLEC5A tSNPs and CAL
Formation, IVIG Treatment or Aneurysm Formation in
KD Patients. In this study, 37 patients (9.9%) had CAL
formation and 49 patients (13.1%) had resistance to the
initial IVIG treatment (Table 1). However, no tSNPs were
signiﬁcantly associated with genotype or allele frequency in
the KD patients with or without CAL formation (Table 3).
Additionally, the CLEC5A polymorphisms tested in this
study failed to show any signiﬁcant associations with geno-
type or allele frequency in the KD patients who showed a
response to IVIG treatment (Table 4).
3.3. Haplotype Analysis of CLEC5A Genetic Polymorphisms in
the Susceptibility, CAL Formation, and IVIG Treatment of KD
Patients. We also calculated pairwise linkage disequilibrium
(LD) of the SNPs (see Supplemental Figure 1 in supplemen-
tary material available online at doi:10.1155/2012/398628)
and analyzed the relationship between the haplotypes of
CLEC5A and susceptibility to KD (Supplemental Table 1),
CAL formation (Supplemental Table 2) and IVIG treatment
response (Supplemental Table 3) in the KD patients. How-
ever, none was signiﬁcantly associated with the phenotype.
4. Discussion
The C-type lectin-like super domain (CTLD) family has di-
verse functions, and in particular, is important in innate im-
munity including nature killer (NK) function or pathogen
recognition [25]. CLEC5A belongs to the Group V “NK cell
receptors” family, and MDL-1 expression is upregulated in
activated myeloid cells [26] and acts as a signaling receptor
for proinﬂammatory cytokine and chemokine release [14].
Even though a number of reports have demonstrated that
KD involves activation of a wide array of immunological
elements such as T cells and macrophages [16–18, 27], with
the subsequent release of several cytokines [28], only a few4 Journal of Biomedicine and Biotechnology
Table 4:GenotypeandallelefrequenciesoftheCLEC5AgeneinpatientswithKawasakidiseaserespondingornotrespondingtointravenous
immunoglobulin (IVIG) treatment.
Genotype
Resistant
(%)
(n = 49)
Responsive
(%)
(n = 326)
Allele
Resistant
(%)
(n = 49)
Responsive
(%)
(n = 326)
Genotype P
value
Dominant
P value
Recessive P
value
Allelic P
value
rs1285968
GG 7 (14.6) 63 (19.4) G 37 (38.5) 286 (44.0)
0.602 0.397 0.427 0.314 AG 23 (47.9) 160 (49.2) A 59 (61.5) 364 (56.0)
AA 18 (37.5) 102 (31.4)
rs11770855
GG 12 (24.5) 74 (23.1) G 52 (53.1) 308 (48.1)
0.437 0.205 0.833 0.363 AG 28 (57.1) 160 (50.0) A 46 (46.9) 332 (51.9)
AA 9 (18.4) 86 (26.9)
rs1285935
AA 2 (4.1) 27 (8.3) A 25 (25.5) 181 (27.8)
0.567 0.954 0.303 0.629 GA 21 (42.9) 127 (39.1) G 73 (74.5) 469 (72.2)
GG 26 (53.0) 171 (52.6)
rs1285933
TT 2 (4.1) 7 (2.2) T 15 (15.3) 121 (18.7)
0.267 0.233 0.414 0.421 CT 11 (22.4) 107 (33.0) C 83 (84.7) 527 (81.3)
CC 36 (73.5) 210 (64.8)
reports have addressed the role of lectin in the pathogenesis
of KD.
Several genetic associations with susceptibility to KD
and CAL formation have been reported, but the results are
inconsistent [29–32]. Previous genetic association studies
have indicated that the intronic SNP (rs28493229) of ITPKC,
1,4,5-trisphosphate 3-kinase C, reduces gene expression by
altering splicing eﬃciency, and the C allele contributes to
immune hyperreactivity in KD patients [29]. Recently, it
has been demonstrated that rs28493229 is associated with
susceptibility to KD and CAL formation [24, 29]. ITPKC is
able to regulate the immune system via calcium-dependent
NFAT pathways [29]. Similarly, previous studies have indi-
cated that C-type lectin receptors (CLRs) are critical in
the activation of the Syk-mediated NFAT signaling pathway
[33]. In addition, CLEC5A has been shown to play a key
role in host defense and to be involved in dengue virus-
mediated disease [14]. This ﬁnding suggests CLEC5A may
beapotential targetprotein thatinvolves calcium-dependent
immune regulation and contributes to the development of
coronary artery lesions. However, we did not ﬁnd evidence
to support a genetic role of CLEC5A in the pathogenesis
of KD. Since we picked tagging SNPs from the HapMap
database,onlythetaggingSNPswithaminorallelefrequency
of more than 10% were selected. Although our tSNP could
capture majority of the underlying genetic variances with
MAF > 10% across the CLEC5A gene, the rare causal genetic
polymorphisms in CLEC5A may not have been detected
in this study. Therefore, we cannot rule out or exclude
rare causal genetic polymorphisms in CLEC5A. In addition,
there are, at least, seventeen groups of CLRs in vertebrates.
Indeed, it has been reported that mannose-binding lectin
gene polymorphisms are associated with susceptibility to
KD [34] and CAL formation [35]. Thus, large-scale DNA
sequencingtoCLRfamilyisneededtobetterunderstandKD.
In conclusion, this study showed for the ﬁrst time that
tSNPs of CLEC5A are not associated with susceptibility to
KD, CAL formation, and IVIG treatment response in a
Taiwanese population.
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